United Therapeutics Corporation

UTHRleader

United Therapeutics focuses on life-saving treatments for pulmonary arterial hypertension and is pioneering xenotransplantation — using genetically modified pig organs for human transplant. It has over $5B in cash and no long-term debt.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($2.8B)

Data statis (memuat keuangan langsung…)

Tyvaso Products (55%)

Remodulin (25%)

Orenitram (12%)

Other (8%)

Komposisi segmen dan pelanggan utama

Detail produk

Tyvaso / Tyvaso DPI (Inhaled Treprostinil)55%

Pulmonary arterial hypertension (PAH) + pulmonary hypertension associated with ILD. Fastest-growing drug.

Remodulin (Treprostinil Infusion)25%

Continuous subcutaneous/IV infusion for severe PAH.

Orenitram (Oral Treprostinil)10%

Oral extended-release treprostinil for PAH.

Unituxin / Transplant Pipeline10%

Pediatric neuroblastoma + regenerative medicine (xenotransplantation organs).

Hubungan Rantai Pasok

Konteks makro dan pasar

헬스케어Berita sektor

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Katalis mendatang

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok United Therapeutics Corporation.

Info Perusahaan

Kantor Pusat

Silver Spring, MD

Didirikan

1996

Karyawan

2,600

Situs Web

unither.com

Gambaran umum sektor — 헬스케어

Berita sektor